Drug
Zolbetuximab clinical trials
Also written IMAB362 and Vyloy.
Keep track of what changes. Save the zolbetuximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2025 | 5 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 6
Astellas Pharma Global Development, Inc. (7) · Ganymed Pharmaceuticals GmbH (2) · Astellas Pharma Inc (1) · Astellas Pharma China, Inc. (1) · Midhun Malla (1) · China Medical University, China (1) · National Cancer Center, Japan (1) · American Association for Cancer Research (1)
Often tested with
Tested in the same studies.
Oxaliplatin (2) · Modified FOLFIRINOX Regimen (1) · Modified FOLFOX6 Regimen (1) · CAPOX Regimen (1) · Trastuzumab (1) · Adebrelimab (1) · Apatinib (1) · Tegafur (1)
Studies
Open first, then newest update. How each study uses zolbetuximab is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT06901531Written as zolbetuximab
- Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2National Cancer Center, JapanNCT07872722Written as Zolbetuximab
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasRecruitingPhase 2American Association for Cancer ResearchNCT07290985Written as Zolbetuximab
- A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerNot yet recruitingPhase 4Astellas Pharma Global Development, Inc.NCT07829757Written as Zolbetuximab
- Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract CancersNot yet recruitingPhase 2Midhun MallaNCT07723534Written as Zolbetuximab
- Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal CancerRecruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT06962137Written as zolbetuximab
- A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric CancerRecruitingPhase 1/2Asan Medical CenterNCT06732856Written as zolbetuximab
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingPhase 2China Medical University, ChinaNCT06881017Written as zolbetuximab
- A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.Active, not recruitingPhase 3Astellas Pharma Global Development, Inc.NCT03504397Written as zolbetuximab
- A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic CancerActive, not recruitingPhase 1Astellas Pharma Global Development, Inc.NCT06396091Written as zolbetuximab
- A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerActive, not recruitingPhase 2Astellas Pharma Global Development, Inc.NCT03816163Written as zolbetuximab
- A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Active, not recruitingPhase 3Astellas Pharma Global Development, Inc.NCT03653507Written as zolbetuximab
- Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric CancerCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01630083Written as zolbetuximab
- Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal CancerCompletedPhase 2Ganymed Pharmaceuticals GmbHNCT01197885Written as IMAB362
- A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNot applicableAstellas Pharma IncNCT03528629Written as Zolbetuximab
- Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerCompletedPhase 1Ganymed Pharmaceuticals GmbHNCT00909025Written as Claudiximab
- A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedPhase 1Astellas Pharma China, Inc.NCT04086758Written as zolbetuximab
Given in every arm · 4 — zolbetuximab is usual care beside what is tested
- Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) AdenocarcinomaNot yet recruitingPhase 1/2Kaohsiung Medical University Chung-Ho Memorial HospitalNCT07680569Written as Zolbetuximab
- Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric CancerRecruitingPhase 2Shanghai Zhongshan HospitalNCT06468280Written as Zolbetuximab
- A Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerActive, not recruitingPhase 2Astellas Pharma Global Development, Inc.NCT03505320Written as zolbetuximab
- Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric CancerCompletedPhase 1Astellas Pharma Global Development, Inc.NCT01671774Written as IMAB362
As the comparator · 1 — what is tested is compared with zolbetuximab
Codes
What other systems call zolbetuximab · ClinicalTrials.gg INT006409
- MeSH (NLM) C585662zolbetuximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TF5MPQ8WGYZOLBETUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q17107865zolbetuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C85475ZolbetuximabOne source FDA
- DrugBank DB15118One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585662 | zolbetuximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TF5MPQ8WGY | ZOLBETUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q17107865 | zolbetuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C85475 | Zolbetuximab | One source FDA |
| DrugBank | DB15118 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.